• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI and Shionogi to cancel agreement

Article

Ultrasound contrast agent developer Molecular Biosystems of SanDiego announced last week that it has exchanged breach-of-contractnotices with its Japanese licensee, Shionogi & Co. of Osaka.MBI said that the two companies have been unable to agree on

Ultrasound contrast agent developer Molecular Biosystems of San

Diego announced last week that it has exchanged breach-of-contract

notices with its Japanese licensee, Shionogi & Co. of Osaka.

MBI said that the two companies have been unable to agree on terms

for canceling their relationship, which covers distribution of

MBI's Albunex agent in Japan, Taiwan, and South Korea. MBI claims

that Shionogi has not diligently pursued the development and distribution

of Albunex in its territory, while Shionogi claims that MBI supplied

it with batches of Albunex that fail to meet adequate quality

standards. MBI said that it will pursue another licensee for Albunex

in the territory.

Recent Videos
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.